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Abstract
Oral azole antifungal therapy is used extensively for all forms of aspergillosis, including allergic bronchopulmonary aspergillosis
(ABPA). However, long-term therapy may increase the risk of resistance. Here we report itraconazole and voriconazole resistance
with reduced susceptibility to posaconazole in Aspergillus fumigatus in two patients exposed to itraconazole. Patients were diagnosed
with ABPA and Aspergillus bronchitis related to innate immune defects. An azole susceptible strain was initially isolated from patient
1, but later a genetically different azole-resistant strain was cultured, possibly related to sub-therapeutic itraconazole levels, which
could be a trigger for selection of resistance. The mechanism of resistance identiﬁed in this case was an L98H change in Cyp51A,
accompanied by a tandem repeat in the promoter region of cyp51A leading to increased expression. No cyp51A mutation was
found in azole-resistant isolates recovered from patient 2. Both patients responded to posaconazole, with plasma levels of
>1.0 mg/L. Subsequently, susceptible strains of different molecular types were cultured from both patients, suggesting eradication
and replacement.
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Introduction
Allergic aspergillosis is a hypersensitivity disease manifesting
in several clinical forms, including allergic bronchopulmo-
nary aspergillosis (ABPA). ABPA is characterized by wheez-
ing, bronchiectasis, pulmonary inﬁltrates and sputum
containing brown plugs [1,2]. Asthmatics and cystic ﬁbrosis
patients are primarily at risk [2]. As ABPA is a long-term
condition, its prevalence is higher than invasive aspergillosis
(IA), but its annual incidence or rate of new diagnoses
are probably lower. In addition to the conventional corti-
costeroid treatment, itraconazole (ITC) antifungal therapy
has been shown to be advantageous in 60% of cases
[3].
Aspergillus bronchitis (or aspergillary bronchitis, as it was
ﬁrst called) [4] may occur in patients with underlying pulmo-
nary or airway pathology [5], especially in the context of
lung transplantation [6,7]. Antifungal therapy is probably
effective if it has not evolved into pseudomembranous Asper-
gillus tracheobronchitis, which is usually fatal.
The azoles are the largest and most widely used class of
antifungal drugs. Although voriconazole (VRC) is regarded as
ﬁrst-line therapy for invasive aspergillosis [5], ITC is still
commonly used for chronic non-invasive forms of aspergillo-
sis. Resistance to ITC in Aspergillus fumigatus, the species
which causes the vast majority of cases of allergic aspergillo-
sis, is well recognized. In our experience, it occurs mainly in
patients with chronic forms of aspergillosis, particularly
chronic cavitary pulmonary aspergillosis (CCPA) with asperg-
illomas. The frequency of ITC resistance in clinical A. fumiga-
tus strains since the turn of the millennium (when most
cases have been reported) is between 2% and 3%, and it can
increase up to 6% depending on the area from which it is
reported [8–10]. Cross-resistance between other azole
drugs has also been reported [11,12]. To our knowledge,
azole resistance has not been described among isolates caus-
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ing allergic aspergillosis. In this report, we describe azole
resistance in two patients with ABPA and Aspergillus bronchi-
tis undergoing ITC therapy.
Case Reports
Patient 1
A 47 year-old asthmatic woman was diagnosed with ABPA.
Her previous medical history was quite complex, including
aortic valve replacement (twice), hypertension, hypermobility
syndrome, perennial rhinitis and multiple allergies, including
allergies to various houseplants, house dust, horses, dogs
and pollen. The patient reported breathlessness especially on
exercise. Cough was a predominant symptom, with dis-
coloured brown sputum with hard brown plugs (which had a
tree branch appearance). She had required several courses
of oral corticosteroids for exacerbations. A computed
tomography (CT) scan performed in January 2006 revealed
some prominence and dilatation of the central bronchial tree
consistent with mild bronchiectasis. There was no evidence
of ﬁbrosis or other parenchymal disease. She had normal
immunoglobulin levels and eosinophil counts, with a total
serum IgE of 3000 IU/mL and an anti-Aspergillus IgE of
94.5 IU/mL. A radioallergosorbent test (RAST) (IgE) was
positive against several other fungi, including Penicillium
(13.3), Alternaria (13.9), Candida albicans (4.4), Saccharomyces
cerevisiae (1.3) and Cladosporium (1.0). Also, serum precipitins
against A. fumigatus were at the limit of detection.
In July 2006, ITC treatment was started (capsules,
200 mg daily) while the patient was treated with omepra-
zole, which led to reduced cough. In October 2006, culture
of her sputum yielded A. fumigatus susceptible to ITC (labo-
ratory number F15767). Random serum ITC levels mea-
sured using a bioassay [13,14] in October 2006 were
below the level of detection (<0.8 mg/L). She was also
found to have very low mannose-binding lectin levels
(0.3 mg/L; normal >4 mg/L). The patient was then treated
with ITC oral solution (400 mg daily) which she found very
difﬁcult to tolerate as a result of nausea and diarrhoea.
Nevertheless, an adequate, randomly tested serum
ITC level (5.2 mg/L) was observed in November 2006, as
determined with a bioassay [13,14].
Sputum culture performed in January 2007 revealed Myco-
bacterium xenopi. Because of drug interactions between the
rifamycins and ITC, the patient was treated with ethambutol
and ciproﬂoxacin in combination with ITC. Previous severe
cholestasis under erythromycin therapy as a child precluded
the use of a macrolide.
In February 2007, while being treated with a ITC solution,
her sputum was abundantly yellow and thick, and the patient
reported feeling very tired. Sputum culture revealed heavy
growth of A. fumigatus (F16216), which was azole resistant
(Table 1). In June 2007, posaconazole (PSC) was prescribed
as salvage therapy. Over the next 6 months, her health was
reasonable under PSC treatment. PSC serum levels were
randomly measured using a bioassay (18th European Con-
gress of Clinical Microbiology and Infectious Diseases,
abstract P1351) between July 2007 and December 2008 and
ranged from 1.01 to 1.36 mg/L. After a stormy course
involving a lung abscess and a probably non-cardiogenic pul-
monary oedema requiring mechanical ventilation in early and
late 2008, respectively, during which VRC, amphotericin B
(AMB) and PSC were used sequentially, an azole-susceptible
A. fumigatus was isolated (F18830).
Patient 2
A 41 year-old female engineer who visited building sites suf-
fered from intermittent haemoptysis and was diagnosed with
bilateral lower-lobe bronchiectasis in 1999. She was a non-
smoker and denied any constitutional upset, chest pain or
shortness of breath. Since 1999 she had required antibiotics
TABLE 1. Minimum inhibitory concen-
tration results (MIC, mg/L) and cyp51A
mutations found in Aspergillus fumigatus
isolates. Minimum fungicidal concentra-




alterationITC VRC PSC RVC AMB
Patient 1
F15767 0.25 (0.5) 0.5 0.06 0.5 0.25 (1) None
F16216 >8 8 2 8 0.125 (0.5) L98H + promoter
alteration
F18830 0.25 0.5 0.125 ND 0.5 (2) ND
Patient 2
F16311 >8 8 1 (2) 4 0.25 (0.5) None
F16351 >8 4 (8) 0.5 (2) 4 0.25 (1) None
F18718 1 2 0.125 ND 0.5 (>8) ND
ITC, itraconazole; VRC, voriconazole; PSC, posaconazole, RVC, ravuconazole; AMB, amphotericin B; ND, not
determined.
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approximately three to four times per year, with little spu-
tum production between episodes of infection. Additional
past medical history included perennial rhinitis for which
she took no medication; there was no history of asthma. She
had bilateral extensive foot onychomycosis for which
she had been prescribed ITC capsules, 1 week course per
month for 3 months, without success. Plasma ITC levels
were not determined. She had a normal sinus CT scan and
her lung function was normal.
Since January 2007, the patient reported a chronic cough
with variable amounts of sputum, yellow to green in colour.
She did not improve despite two courses of amoxicillin-
clavulanate. She reported feeling increasingly unwell and more
breathless, without any wheezing or chest pain. Blood analy-
ses showed positive Aspergillus precipitins (titre 1/8). IgE levels
were within the normal range and RAST against A. fumigatus was
negative. There was no eosinophilia, and the serum C-reac-
tive protein level was low at 2 mg/L. She was deﬁcient in
mannose-binding lectin (0.65 mg/L) with a non-functional
genotype (HYPA LYPB). Her anti-Haemophilus inﬂuenzae and
anti-Clostridium tetanus antibody levels were within the normal
range but anti-pneumococcal antibody levels were low. She
was subsequently vaccinated with pneumococcal vaccine. In
March 2007, treatment was started with ITC capsules
(200 mg twice per day), but as sputum showed heavy growth
of ITC-resistant A. fumigatus (F16311 and F16351), ITC was
discontinued. Her a1-antitrypsin level was also low (0.2 g/L)
with a ZZ genotype, and her cystic ﬁbrosis genotype was
wild-type homozygous. Treatment with PSC solution (400 mg
twice daily) was started in June 2007. A random serum PSC
level in July was 3.03 mg/L. The patient developed no side
effects and over 3 months of PSC therapy had a complete
resolution of her cough and generalized symptoms. Unfortu-
nately, she relapsed 3 weeks after discontinuing therapy (with
haemoptysis and dyspnoea) but responded to re-introduction
of PSC which was continued for 6 weeks. A random serum
PSC level measured during December 2007 was 1.07 mg/L. In
May 2008, her sputum culture yielded A. fumigatus, resistant
to ITC and VRC and susceptible to PSC, after another epi-
sode of mild haemoptysis, which was not treated. In Septem-
ber 2008, an azole-susceptible A. fumigatus was isolated
(F18718). Throughout 2007 and 2008, Aspergillus precipitins
were detectable at a titre of 1/8.
Materials and Methods
Isolates
Aspergilli were identiﬁed as A. fumigatus, according to macro-
and micro-morphological characteristics, and subcultured at
50C to exclude A. lentulus. Isolates are held in the Regional
Mycology Laboratory, Manchester culture collection.
Susceptibility testing
Susceptibilities were determined in triplicate using a modiﬁed
EUCAST method [15]. ITC (Research Diagnostics Inc., Con-
cord, CA, USA), VRC (Pﬁzer Ltd, Sandwich, UK), PSC
(Schering-Plough, NJ, Kennilworth, USA), ravuconazole
(RVC; Eisai, Woodcliff Lake, NJ, USA) and AMB (Sigma,
Poole, UK) were serially diluted to provide a ﬁnal drug
concentration range of 8–0.015 mg/L. RPMI-1640 (Sigma)
was supplemented with glucose (2%) (Sigma). Inocula were
prepared in phosphate-buffered saline with 0.05% Tween 80
(Sigma), quantiﬁed using a haemocytometer, and adjusted to
give a ﬁnal concentration of 5 · 104 CFU/mL. Spore suspen-
sions were loaded into ﬂat bottomed microtitre plates
(Costar Corning, Lowell, MA, USA) and incubated at 37C
for 48 h. Minimum inhibitory concentrations (MICs) were
deduced visually, with a no-growth endpoint. A putative
resistance breakpoint of >2 mg/L was used for ITC, VRC
and RVC, and >0.5 mg/L for PSC. Minimum fungicidal con-
centrations were also determined [16].
Molecular techniques
DNA was extracted using the FastDNA SPIN kit (Q-Bio-
gene, Carlsbad, CA, USA) according to the manufacturers’
instructions. The promoter and the entire coding region of
the cyp51A gene were ampliﬁed. Reaction mixes (25 lL)
were prepared consisting of PCR Master Mix (Promega,
Southampton, UK; providing ﬁnal concentrations of 1.5 mM
MgCl2, 200 lM each dNTP and 0.625 U Taq DNA polymer-
ase), 500 nM of each primer and approximately 15 ng DNA.
PCR ampliﬁcation was conducted on a QB-96 thermal cycler
(Quanta Biotech, Surrey, UK), conditions and primers were
as described previously [12]. Amplicons were puriﬁed using
the QIAquick PCR puriﬁcation kit (Qiagen, West Sussex,
UK). Both strands were sequenced with eight primers in
total [12] using the BigDye Terminator Ready Reaction Mix
version 1.1, on an ABI 3730 Genetic Analyser (Applied Bio-
systems, Warrington, UK).
Microsatellite typing was conducted by ampliﬁcation of six
loci (3A, 3B, 3C, 4A, 4B and 4C) as previously described
[17], except that PCR reactions were not multiplexed. Capil-
lary electrophoresis was carried out on an ABI PRISM
3130xl Genetic Analyser (Applied Biosystems).
Sequences were aligned and mismatches identiﬁed using
AlignX (Invitrogen, Paisley, UK) by comparison to an azole-
susceptible strain (Genbank accession number AF338659).
Mutations were conﬁrmed by repeating PCR and sequencing
of both strands using the closest forward and reverse prim-
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ers. Microsatellite data were analysed using PEAK SCANNER
Software v1.0 (Applied Biosystems) and adjusted using a cor-
rection factor from sequenced alleles [18] to determine the
size of the allele.
Results
Susceptibility results are shown in Table 1. A. fumigatus was
ﬁrst isolated from patient 1 in October 2006 (laboratory
number F15767), which was azole-sensitive. Four months
later (February 2007), a resistant isolate was cultured
(F16216). Cross-resistance was seen between all four azoles
that were tested (Table 1). Subsequently, a susceptible iso-
late (F18830) was cultured in October 2008. Two azole
cross-resistant isolates of A. fumigatus were cultured from
patient 2 in February and March 2007 (F16311 and F16351),
and in September 2008 a susceptible isolate (F18718) was
recovered. Susceptibility to AMB was retained in all isolates.
A change from CTC to CAC at codon 98 in cyp51A
resulting in an L98H change was found in the azole-resistant
isolate F16216 from patient 1. In addition, F16216 was found
to have a 34-base tandem repeat (5¢-GAATCACGCGGTCC
GGATGTGTGCTGAGCCGAAT-3¢) in the promoter region
of the cyp51A gene. No cyp51A mutations were found in the
azole-resistant isolates from patient 2, or the initial suscepti-
ble isolate from patient 1, compared with the wild type
(AF338659). Genbank accession numbers for cyp51A
sequences are as follows: EU807919 (F15767), EU807920
(F16216), EU807921 (F16311) and EU807922 (F16351). The
cyp51A gene of the later azole-susceptible isolates from
either patient was not sequenced.
Microsatellite typing (data not shown) revealed that all
three isolates recovered from patient 1 (F15767, F16216 and
F18830) were genetically unrelated, whereas typing of azole-
resistant isolates from patient 2 (F16311 and F16351) very
strongly suggested that the two isolates are of the same
molecular type. The subsequent susceptible isolate (F18718)
from this patient was genetically distinct.
Discussion
Here we describe the occurrence of azole resistance in two
patients with allergic aspergillosis treated with ITC. Of major
concern is the reduction in susceptiblity to VRC and PSC in
both cases (Table 1), given the limited number of oral agents
curently available for the treatment of aspergillosis.
Currently, the primary mechanism of azole resistance
reported in Aspergilli is related to alterations of the Cyp51
enzyme. Azoles act by disrupting the ergosterol biosynthetic
pathway, speciﬁcally by inhibiting lanosterol 14a-demethylase
(Cyp51), resulting in fungal cell instability. Amino acid
changes may alter protein structure and as a result affect
drug binding and thereby conferring resistance. In patient 1,
cyp51A sequencing of a resistant isolate (F16216) revealed a
mutation at codon 98 (resulting in a L98H change). Thus far
this mutation has always been accompanied by a 34-bp tan-
dem repeat in the promoter region (as is the case here),
resulting in an eight-fold increase in expression of cyp51A
[19]. The combination of the two alterations has been
shown to be crucial to yield this level of resistance [19].
No cyp51A mutations were found in the azole-resistant
isolate from patient 2, suggesting the action of another as
yet ill-deﬁned mechanism. Patient 2 had previously been
exposed to ITC (for onychomycosis), although drug levels
were not determined. The prior use of low-dose and inter-
mittent ITC (pulse therapy) may have precipitated the devel-
opment of azole resistance in this case.
We performed molecular typing of the isolates recovered
from both patients. Microsatellites are short tandem repeats
of DNA which are highly polymorphic, and consequently can
be used in a highly discriminatory test to type strains. Six
microsatellite loci were tested, which provides a high
discriminatory power. The results strongly suggest that the
three isolates from patient 1 are all different strains. Patient
1 had evidence of subtherapeutic serum ITC levels, as a
result of poor bioavailability, which probably increased the
risk of drug resistance.
Interestingly, genetically distinct susceptible A. fumigatus
isolates were subsequently obtained from both patients. It
would have been opportune to analyse several colonies in
these cases, as it is possible that the patients had mixed
infections, but unfortunately only single colonies were
referred for testing. Eradication of azole-resistant strains has
not previously been demonstrated. PSC levels in both
patients were adequate. In patient 1, VRC and/or AMB may
have played a part in the eradication of the resistant A. fumi-
gatus isolate.
The cases reported here suggest that exposure to sub-
therapeutic levels of ITC is a potential trigger for the
development of azole resistance. The ideal lower limit of
ITC plasma (and tissue) concentrations has not been deter-
mined, either for response to therapy or prevention of
resistance. ITC plasma levels are highly variable, reﬂecting
the dose used, oral bioavailability (which is often compro-
mised with capsules), rate of metabolism primarily by
CYP3A4 and key drug interactions. We utilize an ideal
range of 5–15 mg/L for bioassay, based on a higher fre-
quency of failure at lower concentrations and more adverse
686 Clinical Microbiology and Infection, Volume 16 Number 6, June 2010 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 683–688
events at higher concentrations. Long-term exposure to
ITC [20] and VRC may also lead to resistance [12,19–22].
Acquisition of a resistant isolate from the environment,
potentially mediated by agrochemical azole exposure, is also
a possibility [10].
Since the ﬁrst report of ITC resistance in 1997 [20], sev-
eral further cases have been documented in patients with
invasive and chronic pulmonary aspergillosis. However, this
is the ﬁrst report of azole resistance in ABPA and in another
superﬁcial disease. (Outline clinical information reported as
patients 8 and 10 respectively in another report [23]). Given
the frequent use of ITC for allergic aspergillosis, in both
asthmatic and cystic ﬁbrosis patients, this ﬁnding is of con-
cern and suggests that azole susceptibility testing should be
become an integral part of the management of these patients,
especially if they are poorly responsive to therapy, or deteri-
orate after an initial response. Limited therapy options, in
particular oral choices, require increased vigilance for azole
cross-resistance.
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